CL2021000309A1 - Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain. - Google Patents

Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain.

Info

Publication number
CL2021000309A1
CL2021000309A1 CL2021000309A CL2021000309A CL2021000309A1 CL 2021000309 A1 CL2021000309 A1 CL 2021000309A1 CL 2021000309 A CL2021000309 A CL 2021000309A CL 2021000309 A CL2021000309 A CL 2021000309A CL 2021000309 A1 CL2021000309 A1 CL 2021000309A1
Authority
CL
Chile
Prior art keywords
acetaminophen
methods
pharmaceutical preparations
treating pain
sebacoyl dinalbuphine
Prior art date
Application number
CL2021000309A
Other languages
Spanish (es)
Inventor
Oliver Yoa-Pu Hu
Yen-Lun Chen
Original Assignee
Jacob Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacob Biotech Ltd filed Critical Jacob Biotech Ltd
Publication of CL2021000309A1 publication Critical patent/CL2021000309A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente patente de invención está relacionada principalmente con preparaciones farmacéuticas de sebacoilo dinalbufina y acetaminofén y métodos para tratar el dolor.The present patent of invention is mainly related to pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain.

CL2021000309A 2018-09-03 2021-02-05 Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain. CL2021000309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/103786 WO2020047703A1 (en) 2018-09-03 2018-09-03 Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain

Publications (1)

Publication Number Publication Date
CL2021000309A1 true CL2021000309A1 (en) 2021-07-19

Family

ID=69721971

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000309A CL2021000309A1 (en) 2018-09-03 2021-02-05 Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain.

Country Status (11)

Country Link
EP (1) EP3846815A4 (en)
JP (2) JP7318987B2 (en)
KR (1) KR20210054560A (en)
CN (1) CN113164469A (en)
AU (1) AU2018440280B2 (en)
CA (1) CA3111271A1 (en)
CL (1) CL2021000309A1 (en)
IL (1) IL280822A (en)
SG (1) SG11202101974WA (en)
WO (1) WO2020047703A1 (en)
ZA (1) ZA202102209B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237140A (en) * 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
DE602007002154D1 (en) * 2007-03-02 2009-10-08 Flamek Corp Oue Analgesic composition of topically applied, non-steroidal and anti-inflammatory drugs and opioids
PL3069733T3 (en) * 2013-11-13 2023-02-13 National Defense Education And Research Foundation New acetaminophen compound composition without side effect to liver

Also Published As

Publication number Publication date
CA3111271A1 (en) 2020-03-12
JP2023078480A (en) 2023-06-06
IL280822A (en) 2021-04-29
ZA202102209B (en) 2022-03-30
JP2021535216A (en) 2021-12-16
CN113164469A (en) 2021-07-23
WO2020047703A1 (en) 2020-03-12
AU2018440280B2 (en) 2022-11-03
JP7318987B2 (en) 2023-08-01
AU2018440280A1 (en) 2021-03-18
KR20210054560A (en) 2021-05-13
EP3846815A4 (en) 2022-05-04
SG11202101974WA (en) 2021-03-30
EP3846815A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
ECSP19043710A (en) AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF LIVER DISEASES
EA201891083A1 (en) COMPOSITIONS OF ANTIBODIES TO CD38 FOR SCRAPTURE AND THEIR APPLICATION
CL2020002043A1 (en) Methods and compositions for the delivery of therapeutic proteins.
CO2018013077A2 (en) Arginase inhibitors and their therapeutic applications
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
ECSP21093541A (en) COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
CL2018000622A1 (en) Triazole thienodiazepine acetamide and its related uses.
EA201991073A1 (en) MAGL INHIBITORS
CL2021001395A1 (en) Compounds derived from cyclic pantheines; pharmaceutical composition comprising them; and its use to increase the concentrations of acetyl-coa, for the treatment of cancer, inflammatory disease, neurodegenerative disease, multiple sclerosis, among other diseases.
EA201990598A1 (en) HIGHLY CONCENTRATED LOW VISCOUS DRUGS MASP-2 ANTIBODIES, KITS AND METHODS
EA201991074A1 (en) MAGL INHIBITORS
CO2019002889A2 (en) Combination treatments comprising the administration of imidazopyrazinones
BR112019024566A2 (en) pyrazole magl inhibitors
PL410665A1 (en) Arginase inhibitors and their therapeutical applications
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
CL2019001586A1 (en) Insulin containing pharmaceutical compositions.
EA201891468A1 (en) COMPOSITIONS AND METHODS TO REDUCE TAU EXPRESSION
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
CL2019001053A1 (en) Pharmaceutical formulations and methods to prepare them.
CL2022000967A1 (en) Compositions and methods for the treatment of liver diseases
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
AR113618A1 (en) ANTIMICROBIAL PEPTIDES AND METHODS TO USE THEM
ECSP19066721A (en) DUAL MAGL AND FAAH INHIBITORS